TCC RICARDO ROCHA

Running title: TRANSDERMAL TESTOSTERONE RELIEVING ANDROPAUSE SYMPTOMS

EFFECTS OF NANOSTRUCTURED TRANSDERMAL TESTOSTERONE DELIVERY SYSTEM IN HIPOGONADISM: A CONFOCAL RAMAN SPECTROSCOPY STUDY

Ricardo Rocha*1, Marco Antonio Botelho

1 University Potiguar, Post-graduation Program in Biotechnology, Laboratory of Nanotechnology, Natal/RN, BRAZIL

*Corresponding Author:

Ricardo Rocha, MD
University Potiguar - School of Medicine
Post Graduation Program in Biotechnology
Av. Salgado Filho, 1610 Natal/RN BRAZIL.
Phone: ++ 55 84 3215.1272 / Fax: ++ 55 84 3215.1275
Email: [e-mail]

Introdução
The hormone replacement therapy with testosterone (HRT) is widely used in men with hipogonadism (1, 2). However, there is a permanent debate about benefits and the risks involving this kind of clinical procedure. Previous reports have shown some evidences worsening prostate cancer (3-5).
Recently, Nanotechnology has been proving to be a interesting tool in medical sciences (6) new strategies with nanostructured drugs has brought new and strong evidences that supports the clinical use of this technology (7).
Previous Confocal Raman spectroscopy studies (CRS) were able to show the safe and efficacy of a novel Hormone replacement therapy protocol (6), elected this methodology to validate the efficacy of controlled released drugs. This method can describe in real time relevant information about drugs profile such as depth and concentration of the investigated compound in each layer of the skin.
The present study was designed to determine the short-term effects of transdermal HRT of a nanostructured formulation of BIOLIPID B2® Testosterone (5%) treating signs and symptoms related to hipogonadism and evaluate its effects on clinical, and laboratorial parameters after 3 months follow-up.
There is a lack of scientific studies on the RHT in patients with recurrent prostate cancer. Thus, the aim of this study is to report the effects of TRHT a man with